Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder
November 19, 2018 08:00 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018
November 14, 2018 08:00 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Addiction Drug Developer Adial Pharmaceuticals Receives Notice of Allowance of Canadian Patent for AD04 in Alcohol Use Disorder
November 08, 2018 09:20 ET
|
Adial Pharmaceutical, Inc.
CHARLOTTESVILLE, Va., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Adial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
October 23, 2018 08:00 ET
|
Adial Pharmaceutical, Inc.
CHARLOTTESVILLE, Va., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent
September 18, 2018 07:30 ET
|
Adial Pharmaceutical, Inc.
Patent portfolio significantly enhanced and extended by this patent CHARLOTTESVILLE, Va., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage...
Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results
September 12, 2018 09:00 ET
|
Adial Pharmaceutical, Inc.
Genetically targeted AD04 drug candidate indicates stability at four-year point as it moves toward Phase 3 clinical trial CHARLOTTESVILLE, Va., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Adial...
Adial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern
September 04, 2018 08:00 ET
|
Adial Pharmaceutical, Inc.
CHARLOTTESVILLE, Va., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Leading Addiction Focused Company Adial Pharmaceuticals Comments on Lancet Article Reporting Alcohol is the Number One Cause of Death Globally Among Ages 15 to 49
August 27, 2018 09:00 ET
|
Adial Pharmaceutical, Inc.
Adial seeks to rapidly advance its drug AD04 through Phase 3 trialsto become an important tool in combating alcohol use disorder CHARLOTTESVILLE, Va., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adial...
Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development
August 15, 2018 08:00 ET
|
Adial Pharmaceutical, Inc.
CHARLOTTESVILLE, Va., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent...
Adial Pharmaceuticals Announces Closing of Initial Public Offering
July 31, 2018 16:05 ET
|
Adial Pharmaceutical, Inc.
CHARLOTTESVILLE, Va., July 31, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of a...